A detailed history of Verition Fund Management LLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Verition Fund Management LLC holds 74,274 shares of PCVX stock, worth $2.55 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
74,274
Previous 6,073 1123.02%
Holding current value
$2.55 Million
Previous $497,000 464.19%
% of portfolio
0.01%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 15, 2025

BUY
$37.76 - $92.13 $2.58 Million - $6.28 Million
68,201 Added 1123.02%
74,274 $2.8 Million
Q4 2024

Feb 14, 2025

BUY
$80.97 - $117.93 $145,584 - $212,038
1,798 Added 42.06%
6,073 $497,000
Q3 2024

Nov 14, 2024

BUY
$70.52 - $117.12 $301,473 - $500,688
4,275 New
4,275 $488,000

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $2.04B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Verition Fund Management LLC Portfolio

Follow Verition Fund Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verition Fund Management LLC with notifications on news.